Volume 29, Number 3—March 2023
Research
Increase in Colorado Tick Fever Virus Disease Cases and Effect of COVID-19 Pandemic on Behaviors and Testing Practices, Montana, 2020
Table 1
Characteristic | Case-patients, n = 14 | Controls, n = 22 | OR (95% CI) |
---|---|---|---|
Sex | |||
M | 10 (71) | 12 (55) | 2.1 (0.5–8.3) |
F |
4 (29) |
10 (45) |
0.5 (0.1–2.0) |
Age group, y | |||
<21 | 5 (36) | 4 (18) | 2.5 (0.6–11.0) |
21–44 | 3 (21) | 10 (45) | 0.3 (0.1–1.4) |
45–64 | 5 (36) | 5 (23) | 1.9 (0.4–7.9) |
>65 | 1 (7) | 3 (14) | 0.5 (0.1–3.9) |
Median age, y (range) |
26 (1–70) |
33 (7–84) |
NA |
Race | |||
White |
14 (100) |
22 (100) |
0.6 (0.4–11.7) |
Ethnicity | |||
Non-Hispanic or non-Latino | 12 (86) | 17 (77) | 1.8 (0.3–9.2) |
Hispanic or Latino | 1 (7) | 3 (14) | 0.5 (0.1–3.9) |
Other |
1 (7) |
2 (9) |
0.8 (0.1–6.7) |
Underlying medical condition | |||
None | 11 (79) | 13 (59) | 2.5 (0.6–10.8) |
Immunosuppressive condition or medication | 0 | 2 (9) | 0.3 (0.0–3.6) |
Diabetes mellitus | 0 | 2 (9) | 0.3 (0.0–3.6) |
Cardiovascular disease | 1 (7) | 3 (14) | 0.5 (0.1–3.9) |
Cancer | 0 | 1 (5) | 0.1 (0.0–1.3) |
Other |
2 (14) |
2 (9) |
1.7 (0.3–10.9) |
SARS-CoV-2 testing during illness | |||
Tested | 6 (43) | 7 (32) | 1.6 (0.4–6.3) |
Positive | 0 | 0 | 1.6 (0.1–28.1) |
*Values are no (%) except as indicated. NA, not applicable; OR, odds ratio.
Page created: December 27, 2022
Page updated: February 19, 2023
Page reviewed: February 19, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.